Work

OAB-002: Daratumumab improves depth of response and progression free survival in transplant-ineligible, high-risk, newly diagnosed multiple myeloma (NDMM)

Year: 2021

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(21)02076-0

Authors: Andrzej Jakubowiak, Shaji Kumar, Rohan Medhekar, Huiling Pei, Patrick Lefebvre, Shuchita Kaila, Jianming He, Marie-Helene Lafeuille, Annelore Cortoos, Anil Londhe, Panagiotis Mavros, Thomas Lin, Saad Z. Usmani

Institutions: University of Chicago, Mayo Clinic, Janssen Scientific Affairs (United States), Analysis Group (United States), Janssen Research & Development (United States), Levine Cancer Institute

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3211820995

Cites:

Cited by:

Related to: 10